These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36126186)

  • 21. Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.
    Alexander HC; Nguyen CH; Chu MJJ; Tarr GP; Han CH; Thomas RH; Holden AH; Bartlett ASJR
    J Vasc Interv Radiol; 2022 Dec; 33(12):1559-1569.e2. PubMed ID: 36084842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Jul; ():. PubMed ID: 34294586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and Toxicities after
    Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
    Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.
    She WH; Cheung TT; Yau TC; Chan AC; Chok KS; Chu FS; Liu RK; Poon RT; Chan SC; Fan ST; Lo CM
    Hepatobiliary Surg Nutr; 2014 Aug; 3(4):185-93. PubMed ID: 25202695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis.
    Reimer RP; Reimer P; Mahnken AH
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1545-1556. PubMed ID: 29881933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.
    Vermeulen S; De Keukeleire K; Dorny N; Colle I; Van Den Bossche B; Nuttens V; Ooms D; De Bondt P; De Winter O
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of DLCO changes in patients with relatively higher lung shunt fractions receiving TARE.
    Engur CO; Ozguven S; Soydemir E; Eryuksel E; Sen F; Turoglu HT; Cimsit C; Erdil TY; Ones T
    Ann Nucl Med; 2023 Feb; 37(2):131-138. PubMed ID: 36436111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer.
    Drescher R; Köhler A; Seifert P; Aschenbach R; Ernst T; Rauchfuß F; Freesmeyer M
    Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.
    Chauhan N; Mulcahy MF; Salem R; Benson Iii AB; Boucher E; Bukovcan J; Cosgrove D; Laframboise C; Lewandowski RJ; Master F; El-Rayes B; Strosberg JR; Sze DY; Sharma RA
    JMIR Res Protoc; 2019 Jan; 8(1):e11545. PubMed ID: 30664496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
    Cappelli A; Pettinato C; Golfieri R
    J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.
    Testa S; Bui NQ; Wang DS; Louie JD; Sze DY; Ganjoo KN
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy.
    Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    J Liver Cancer; 2020 Sep; 20(2):160-166. PubMed ID: 37384324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.